论文部分内容阅读
目的:观察米托蒽醌为主的联合化疗方案治疗晚期非小细胞肺癌的近期疗效及安全性。方法:74例经病理确诊的b-期非小细胞肺癌患者非随机分成三组,CMP方案治疗21例,IMP方案治疗25例,并与CAP方案治疗28例比较。结果:CMP、IMP及CAP方案总的缓解率分别为28.6%、44%及32.1%。三方案对鳞癌的缓解率分别为33.3%、53.8%及37.5%;对腺癌的缓解率分别为22.2%、33.3%及25%。在统计学上,CMP、IMP与CAP之间其缓解率无显著性差异(P>0.05),各组间鳞癌与腺癌的缓解率无显著性差异(P>0.05)。三组的心脏毒性均不明显;CMP与CAP之间其骨髓毒性、消化道毒性、脱发等相似(P>0.05);IMP及CAP之间其消化道毒性相似(P>0.05),WBC↓率与脱发有显著性差异(P<0.05),～WBC↓率与PLT↓率有显著性差异(P<0.005)。结论:米托蒽醌为主的联合化疗方案为治疗晚期非小细胞肺癌较有效的方案。IMP方案其骨髓毒性较大,选择时应慎重
Objective: To observe the efficacy and safety of mitoxantrone-based combination chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: Totally 74 patients with pathologically diagnosed b-stage non-small cell lung cancer were randomly divided into three groups: 21 in CMP regimen, 25 in IMP regimen and 28 in CAP regimen. Results: The total remission rates of CMP, IMP and CAP regimen were 28.6%, 44% and 32.1% respectively. The remission rates of the three regimens for squamous cell carcinoma were 33.3%, 53.8% and 37.5% respectively; the remission rates of adenocarcinoma were 22.2%, 33.3% and 25% respectively. There was no significant difference in the remission rate between CMP, IMP and CAP (P> 0.05). There was no significant difference between the two groups in the remission rate of squamous cell carcinoma and adenocarcinoma (P> 0.05). The cardiotoxicity was not obvious between the three groups. The bone marrow toxicity, gastrointestinal toxicity and alopecia were similar between CMP and CAP (P> 0.05). The digestive tract toxicity between IMP and CAP was similar (P> 0.05) (P <0.05). There was a significant difference between ~ WBC ↓ rate and PLT ↓ rate (P <0.005). CONCLUSION: Mitoxantrone-based combination chemotherapy is an effective treatment for advanced non-small cell lung cancer. IMP regimen of bone marrow toxicity, the choice should be careful